Gcore Raises $60 Million in Series A Funding to Drive AI Innovation and Global Expansion
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced it has secured $60 million in Series A funding from institutional and strategic investors. Led by Wargaming, and with participation from Constructor Capital and Han River Partners, this marks the company’s first external capital raise since its inception more than 10 years ago. The funds will be strategically invested in Gcore’s technology and platform, including cutting-edge AI servers powered by NVIDIA GPUs, to drive AI-led innovations. This investment underscores Gcore’s commitment to delivering advanced edge AI solutions that enhance cloud resource efficiency and ensure data sovereignty.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722352056/en/
Gcore, the global edge AI, cloud, network, and security solutions provider (Graphic: Business Wire)
Public organizations, telcos, and global corporations entrust Gcore with their edge workloads due to its expansive network, strong presence in emerging markets, and proven cloud capabilities in AI training and inference. Gcore serves customers across diverse industries, including media and entertainment, gaming, technology, financial services, and retail.
Built for the edge and addressing a $200bn+ market opportunity, Gcore’s cloud infrastructure powers both the training of large language models (LLMs) and the inference of AI applications at the edge. This is enabled by Gcore’s global network of over 180 edge nodes across six continents, including 25+ cloud locations, with a total network capacity exceeding 200 Tbps.
"Gcore has been our partner for over 10 years, helping us deliver games to hundreds of millions of players worldwide. We are excited to support the company on this journey and look forward to helping them become uniquely positioned to lead high-speed AI model training and inference anywhere in the world," said Sean Lee, Chief Corporate Development Officer of Wargaming.
"Constructor Capital is excited to invest in Gcore, a leading player in the AI IaaS space, in a booming market with CAGRs of over 40%. We believe in Gcore’s unique value proposition as a comprehensive provider offering a wide range of edge solutions, high automation, attractive TCO, extremely low latency, and an experienced management team. We look forward to a successful journey together in the years to come," added Matthias Winter, Managing Partner of Constructor Capital.
“We are thrilled to invest in Gcore for its forward-thinking approach to global low-latency AI infrastructure and innovative edge AI solutions,” said Christopher Koh, Managing Partner of HRZ. “We are especially impressed by their leadership in APAC, collaboration with world-class partners, and strategic alignment with emerging AI opportunities in the region.”
“We are on the cusp of an AI revolution that will transform how companies operate,” said Andre Reitenbach, CEO of Gcore. “Gcore is perfectly positioned to connect the world to AI, anywhere and anytime, by delivering innovative AI, cloud, and edge solutions. The growing demand for AI infrastructure from enterprises and SMBs alike highlights the importance of this significant investment.We are thrilled by the support of investors like Wargaming, Constructor Capital, and Han River Partners as we enhance our extensive network of AI servers and reinforce the powerful edge services we offer.”
About Gcore
Gcore is a global edge AI, cloud, network, and security solutions provider. Headquartered in Luxembourg, with a team of 600 operating from ten offices worldwide, Gcore provides solutions to global leaders in numerous industries. Gcore manages its global IT infrastructure across six continents, with one of the best network performances in Europe, Africa, and LATAM due to the average response time of 30 ms worldwide. Gcore’s network consists of 180 points of presence worldwide in reliable Tier IV and Tier III data centers, with a total network capacity exceeding 200 Tbps.
About Wargaming
Wargaming is an award-winning online game developer and publisher headquartered in Nicosia, Cyprus. Operating since 1998, Wargaming has grown to become one of the leaders in the gaming industry with 15 offices around the world, including studios in Chicago, Prague, Shanghai, Tokyo, Vilnius, Kyiv and Guildford. Millions of players enjoy Wargaming's titles across all major gaming platforms. Our flagship products include the free-to-play hits World of Tanks, World of Warships and World of Tanks Blitz.
About Constructor Capital
Constructor Capital is a science-based global Venture Capital fund specializing in investments in early-stage startups within the software and deep technology sectors. The company offers financial investment, mentorship, and strategic support to innovative companies, focusing on scalable products through research and science. Constructor Capital primarily serves sectors such as software technology, deep technology, and education technology.
About Han River Partners
Han River Partners (HRZ) is a globally minded venture investment firm with a focus on the Korea-graph, fundamentally driven by transformative opportunities emerging through disruptive technological innovation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722352056/en/
Contacts
Gcore press contact
pr@gcore.com
Agency contact
gcore@ascendcomms.net
+44 (0)7719 863333
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom